- Home
- MGNX
MGNX
MacroGenics Inc.
as 07-05-2024 4:00pm EST
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV × CD3).
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | Rockville |
| Market Cap: | 266.2M | IPO Year: | 2013 |
| Target Price: | $12.44 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.14 - $21.88 | Next Earning Date: | 08-07-2024 |
| Revenue: | $43,357,000 | Revenue Growth: | -73.78% |
| Revenue Growth (this year): | 14.72% | Revenue Growth (next year): | 55.18% |
Stock Insider Trading Activity of MacroGenics Inc. (MGNX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Peters Jeffrey Stuart | MGNX | Senior VP and General Counsel | Apr 4 '24 | Sell | $15.07 | 42,500 | $640,475.00 | 8,895 | SEC Form 4 |
| Peters Jeffrey Stuart | MGNX | Senior VP and General Counsel | Apr 4 '24 | Sell | $15.51 | 147 | $2,279.97 | 8,748 | SEC Form 4 |
| Peters Jeffrey Stuart | MGNX | Senior VP and General Counsel | Apr 4 '24 | Sell | $16.38 | 232 | $3,800.16 | 8,516 | SEC Form 4 |
| Peters Jeffrey Stuart | MGNX | Senior VP and General Counsel | Apr 4 '24 | Sell | $17.74 | 5,351 | $94,926.74 | 3,165 | SEC Form 4 |
| Peters Jeffrey Stuart | MGNX | Senior VP and General Counsel | Apr 4 '24 | Sell | $18.22 | 3,165 | $57,666.30 | 0 | SEC Form 4 |
| Peters Jeffrey Stuart | MGNX | Senior VP and General Counsel | Mar 6 '24 | Sell | $21.50 | 19,625 | $421,937.50 | 8,895 | SEC Form 4 |
| Spitznagel Thomas | MGNX | Sr VP, Technical Ops | Mar 4 '24 | Sell | $20.00 | 10,000 | $200,000.00 | 8,316 | SEC Form 4 |
| Karrels James | MGNX | SVP, CFO and Secretary | Mar 4 '24 | Sell | $20.50 | 30,000 | $615,000.00 | 171,452 | SEC Form 4 |
| Risser Eric Blasius | MGNX | Chief Operating Officer | Mar 4 '24 | Sell | $20.00 | 15,000 | $300,000.00 | 65,059 | SEC Form 4 |
| Risser Eric Blasius | MGNX | Chief Operating Officer | Mar 4 '24 | Sell | $19.63 | 26,159 | $513,501.17 | 38,900 | SEC Form 4 |
| Peters Jeffrey Stuart | MGNX | Senior VP and General Counsel | Feb 26 '24 | Sell | $17.22 | 16,124 | $277,655.28 | 8,895 | SEC Form 4 |
| Bonvini Ezio | MGNX | Sr VP, Research & CSO | Feb 7 '24 | Sell | $18.00 | 3,334 | $60,012.00 | 71,334 | SEC Form 4 |
| Peters Jeffrey Stuart | MGNX | Senior VP and General Counsel | Feb 5 '24 | Sell | $16.50 | 54,376 | $897,204.00 | 21,875 | SEC Form 4 |
| Peters Jeffrey Stuart | MGNX | Senior VP and General Counsel | Feb 5 '24 | Sell | $16.50 | 21,875 | $360,937.50 | 0 | SEC Form 4 |
| Bonvini Ezio | MGNX | Sr VP, Research & CSO | Feb 1 '24 | Sell | $15.00 | 13,316 | $199,740.00 | 74,668 | SEC Form 4 |
| Bonvini Ezio | MGNX | Sr VP, Research & CSO | Jan 19 '24 | Sell | $12.00 | 13,316 | $159,792.00 | 87,984 | SEC Form 4 |
| Bonvini Ezio | MGNX | Sr VP, Research & CSO | Dec 20 '23 | Sell | $10.08 | 18,880 | $190,310.40 | 101,300 | SEC Form 4 |
Latest MacroGenics Inc. News
MGNX Breaking Stock News: Dive into MGNX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
MacroGenics to Participate in Upcoming Investor Conference
Simply Wall St.
a month ago
Shareholders in MacroGenics (NASDAQ:MGNX) are in the red if they invested three years ago
GlobeNewswire
2 months ago
MacroGenics to Participate in Upcoming Investor Conferences
Simply Wall St.
2 months ago
US$15.10: That's What Analysts Think MacroGenics, Inc. (NASDAQ:MGNX) Is Worth After Its Latest Results
The Wall Street Journal
2 months ago
Macrogenics Stock Drops 77% After Study Deaths
GuruFocus.com
2 months ago
Macrogenics Inc (MGNX) Q1 2024 Earnings: Misses Revenue Estimates Amidst Ongoing Clinical ...
Insider Monkey
2 months ago
MacroGenics, Inc. (NASDAQ:MGNX) Q1 2024 Earnings Call Transcript
MT Newswires
2 months ago
Top Midday Decliners
Share on Social Networks:
Disclaimer
The information presented on this page, "MGNX MacroGenics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.